Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
amgen
biotech
boston blog main
boston top stories
life sciences
national blog main
national top stories
new york blog main
3
×
new york top stories
alirocumab
alnylam pharmaceuticals
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
evolocumab
inclisiran
indiana blog main
indiana top stories
national
novartis
pcsk9
raleigh-durham blog main
raleigh-durham top stories
regeneron pharmaceuticals
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
sanofi
seattle blog main
seattle top stories
texas blog main
texas top stories
the medicines company
wisconsin blog main
wisconsin top stories
abeona therapeutics
accent therapeutics
What
drug
3
×
new
3
×
brings
cholesterol
wave
acquire
advantages
agreed
bar
billion
bio
cash
company
compound
deal
drugs
expect
expensive
faces
fda
financial
foe
gamble
healthcare
hint
inhibitors
known
lowering
market
medco
medco’s
medicines
mover
novartis
patients
payers
pcsk
physicians
plan
poised
Language
unset
3
×
Current search:
unset
×
" new york blog main "
×
drug
×
new
×
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
